Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Neuland Laboratories Limited

NSE: NEULANDLABPharmaceuticals

Share price

₹21,015.00

-2.96% close of 8 Oct 2026

Market cap ₹27,320 CrP/E 54.7

Business score

How strong the business is, in one number. The parts behind it are in Pro.

64

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹27,320 Cr

P/E ratio

54.7

P/B ratio

14.4

ROCE

26.5%

ROE

21.2%

Dividend yield

0.2%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹23,995.0052-week low ₹11,555.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 78.3% over the past year, and 11.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 14.6% to 30.5% over the last four years.

Whether it grew faster than its sector

It grew 11.3% a year against a sector median of 13.1% — 1.8 percentage points slower.

Room to re-rate, or risk of de-rating

At 54.7× earnings it costs 2.3× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 31.7×, the 60th percentile of its own range.

Whether growth justifies the valuation

Priced at 1.8 times its growth rate, on earnings growth of 30%.

Profit growthPrice per ₹1 profitPer 1% growth
Neuland Laboratories Limited — this one30%/yr54.7×₹1.8
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 18 of 130 on returns, 67 of 127 on growth, 23 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 26.5% on capital, ahead of 86% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1222 crore of cash from the business, spent ₹904 crore on plant and equipment, and returned ₹121 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 120 arrived as cash (before interest, which is why it can exceed the profit).

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue more than doubled and working-capital days fell from 137 to 84, while the peptide plant start slipped to September

Announced 5 Aug 2026 · Consolidated · Unaudited

Revenue

₹642 Cr

Revenue vs last year

+119.0%

Revenue vs last quarter

-17.3%

Net profit

₹148 Cr

Profit vs last year

+954.8%

Profit vs last quarter

-30.7%

Net margin

23.0%

EPS

₹115.10

Earnings call transcript · 5 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹27,320 Cr
Prev close
₹21,015.00
52w High
₹24,225
52w Low
₹11,500
Enterprise value
₹27,266 Cr
Beta
1.0
Price CAGR 1y
40.0%
Price CAGR 3y
77.0%
Price CAGR 5y
71.0%
Price CAGR 10y
36.0%

Ratios

Return on assets
12.4%
PEG ratio
1.8
P/E ratio
54.7
P/B ratio
14.4
EV / EBITDA
35.7
Industry P/E
38.0
ROCE
26.5%
ROCE 5y average
21.8%
ROE
21.2%
Debt / Equity
0.2
Interest coverage
21.4
Dividend yield
0.2%
ROE 3y average
20.0%
ROE last year
21.0%

Annual P&L

Annual revenue
₹2,023 Cr
Annual profit
₹364 Cr
Operating margin
29.0%
Net profit margin
18.0%
EBITDA margin
28.7%
Sales growth 3y
19.3%
Sales growth 5y
16.6%
Profit growth 3y
30.0%
Profit growth 5y
39.0%
EPS
₹284
Sales growth TTM
78.0%
Profit growth TTM
278.0%
Dividend payout
12.0%

Quarter P&L

Sales latest quarter
₹642 Cr
Profit latest quarter
₹148 Cr
YoY quarterly sales growth
119.2%
YoY quarterly profit growth
957.1%
OPM latest quarter
34.7%

Balance Sheet

Book Value
₹1,442
Face Value
₹10.0
Total debt
₹301 Cr
Total cash
₹355 Cr
Borrowings
₹301 Cr
Reserves / Equity
143.2

Cash Flow

Operating cash flow
₹347 Cr
Free cash flow
-₹50 Cr
FCF yield
-0.3%
Net cash flow
-₹55 Cr

Shareholding

Promoter holding
32.6%
FII holding
21.1%
DII holding
16.5%
Public holding
29.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,764.8533.54,23,4470.902,901.26.015,299.910.520.5
Divi's Lab.9,500.2584.62,52,2020.31902.065.53,080.027.822.0
Torrent Pharma.4,645.5079.21,76,7000.81566.05.84,921.054.915.2
Zydus Lifesci.1,116.2522.91,11,3460.09990.2-35.18,017.022.021.1
Laurus Labs2,029.00100.31,09,6290.10362.1125.52,026.329.117.8
Cipla1,303.8529.41,05,3340.98785.6-39.27,119.32.315.5
Mankind Pharma2,425.2046.91,00,1720.04574.129.64,030.612.913.5
Neuland Labs.21,410.0055.227,4690.16147.7962.4641.6119.226.5
Median416.7034.32,1350.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales363418393385440311398328293514440776642
Expenses266280272278316249311277258359363469419
Material Cost141161228200231229
Change in Inventories-14-48-44-1139-7.75
Purchases of Stock-in-Trade000000
Employee Cost6673808998106
Other Expenses8471958510191
Operating Profit971371211071236287513415677307223
OPM %27333128282022161230184035
Other Income2325254607828128
Exceptional items (within Other Income)000000
Interest2444312255777
Depreciation14151516161616172023242527
Profit before tax831221049213049128391812954287198
Tax %26272227253420292125262625
Net Profit62898168983310228149741213148
EPS in Rs4870635376267922117532166115
Diluted EPS in Rs22117532166115

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4695105795276677639379511,1911,5591,4772,0232,372
Expenses4024304724776086617908079181,0961,1461,4431,609
Material Cost575820
Change in Inventories13-64
Purchases of Stock-in-Trade00
Employee Cost272341
Other Expenses294352
Operating Profit67801065158102147144273463331580763
OPM %1416181091316152330222932
Other Income021434160912902531
Exceptional items (within Other Income)760
Interest2724211916221814131482426
Depreciation15161922263140495360669298
Profit before tax25426714205310582216401346489669
Tax %363630131969232224252526
Net Profit1627471216168164164300260364498
EPS in Rs1831531413136350127234203284388
Diluted EPS in Rs203284
Dividend Payout %870001681086612

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
15%
5 years
17%
3 years
19%
TTM
78%

Compounded profit growth

10 years
29%
5 years
39%
3 years
30%
TTM
278%

Stock price CAGR

10 years
36%
5 years
71%
3 years
77%
1 year
40%

Return on equity

10 years
14%
5 years
18%
3 years
20%
Last year
21%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital99991313131313131313
Reserves1521785375496866977748289811,2701,5121,862
Borrowings18818219231923126418224112895157301
Other Liabilities162155148194200257356302457454498754
Minority Interest00
Total Liabilities5125248861,0711,1301,2311,3251,3831,5801,8332,1802,930
Fixed Assets1231394664755426537167677588249551,177
CWIP414020126104241720414648211
Investments77888874111092
Other Assets3403373934634765475855927819621,0681,541
Total Assets5125248861,0711,1301,2311,3251,3831,5801,8332,1802,930

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity13453911705718960237261317347
Cash from Investing Activity-14-20-42-116-77-49-84-95-61-150-298-423
Cash from Financing Activity1-24-010512-5-11438-136-692521
Net Cash Flow01-4-053-93404244-55
Free Cash Flow-126-2-1217984-37173119112-49

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1008511413490918590111877898
Inventory Days170182186266191209205227211220238245
Days Payable167121118189118110126100129121156129
Cash Conversion Cycle103147182211162190164216193187160214
Working Capital Days11264438138137607481887675
ROCE %161816448111021331926

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters363333333333333333333333
FIIs222324262624222221212021
DIIs6.996.026.546.396.389.09111214151617
Government0.400.400.400.400.400.400.400.400.40000
Public353836353434343433323130
No. of Shareholders26,82427,72328,61629,07734,56739,31539,33342,41944,39346,18746,30444,340

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +33.7% (₹15,717.00 → ₹21,015.00)Brick size ₹728.34 (fixed)Bricks 27
₹15,000₹20,000₹21,015Nov '25Mar '26Jun '26Sep '26
Price moved up one brickPrice moved down one brickLast close ₹21,015.00 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-54.00inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

92,66,997inr

2026-03-31

News

News and filings about Neuland Laboratories Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Key Starting Materials (KSMs) and advanced intermediates

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE794A01010

Plants

  • Peptide Manufacturing Facility · Bonthapally, Telangana
  • Unit I Manufacturing Facility · Bonthapally, Telangana
  • Unit II Manufacturing Facility · Pashamylaram, Telangana
  • Unit III Manufacturing Facility · Gaddapotharam, Telangana

News impact

Big market events that reach Neuland Laboratories Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

24 Jul 2026unspecified₹34
18 Jul 2025unspecified₹12
12 Jul 2024unspecified₹14
11 Jul 2023unspecified₹10
14 Jul 2022unspecified₹5
29 Jun 2021unspecified₹3
10 Nov 2020interim₹2
18 Feb 2020interim₹2

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
6 Aug 2026HDFC MUTUAL FUNDBUY64,547₹21,585.00

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
28 Sep 2026Davuluri Saharsh Rao · Promoter and DirectorBUY10,000—
28 Sep 2026Davuluri Rohini Niveditha Rao · Promoter GroupSELL10,000—

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.